Balancing Speed And Risk In Early Oncology Development

Oncology drug development has never been more complex. Many emerging biotech companies are built around strong science but run on lean teams, with leaders juggling scientific strategy, investor conversations, vendor oversight, and day-to-day operations all at once. At the same time, trials increasingly involve narrow patient populations, complex protocols, biomarker requirements (specific test results patients must have to qualify), competition for enrollment, and growing volumes of data. Drawing on firsthand experience founding and scaling biotech companies, this perspective explores how sponsors can balance the need for speed with the need to manage risk.

The most important decisions often happen before the first patient is enrolled. Choices about protocol feasibility, site strategy, patient identification, and enrollment assumptions can decide a study’s success. For example, a biomarker cutoff that is too strict can exclude much of an already small patient group. As programs expand into multiple studies, indications, and regions, the challenge shifts toward coordination, visibility, and clear decision-making, without losing the agility that drove early progress. Learn how to pressure-test your assumptions early, invest only in the capabilities you need now, and pair strong science with practical operational planning so your oncology program keeps its momentum for the patients who are waiting.